OWC Pharmaceutical Research (OWCP) Stock Price, News & Analysis

Company Overview

OWC Pharmaceutical Research Corp. (OTCMKTS: OWCP) is a biopharmaceutical company focused on the development and commercialization of novel small‐molecule therapeutics targeting central nervous system (CNS) disorders and cancer. The company’s research pipeline comprises both in‐house discovered compounds and licensed assets from academic and industry collaborations. OWC Pharmaceutical Research leverages structure‐based drug design and preclinical pharmacology to advance candidates through toxicity and safety studies toward regulatory filings.

Key therapeutic areas include movement disorders, neurodegenerative diseases and oncology. The company’s preclinical programs feature selective receptor modulators designed to improve efficacy and reduce side effects in conditions such as tardive dyskinesia, Parkinson’s disease and certain solid tumors. OWC’s discovery engine employs in vitro screening, in vivo pharmacology and biomarker strategies to optimize lead molecules and support translational development into clinical trials.

Founded in 2014 and headquartered in Boca Raton, Florida, OWC Pharmaceutical Research maintains research facilities in the United States and collaborative alliances in Europe and Asia. The company actively pursues strategic partnerships and licensing agreements with academic institutions and contract research organizations to expand its R&D capacity and accelerate the progression of its pipeline. Through these collaborations, OWC aims to access complementary expertise and share development risk while retaining key commercial rights.

OWC’s leadership team combines experience in medicinal chemistry, clinical development and regulatory affairs. The board of directors includes seasoned executives with backgrounds in biotech investment and pharmaceutical operations. This management group oversees a streamlined organization designed to advance select candidates efficiently from discovery through regulatory milestones, positioning the company for potential collaboration or licensing deals as its programs mature.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 16,500 shs
• Average Volume: 273,602 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OWCP Stock Analysis - Frequently Asked Questions

How do I buy shares of OWC Pharmaceutical Research?

Shares of OWCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OWC Pharmaceutical Research own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OWC Pharmaceutical Research investors own include Geo Group (GEO), Co-Diagnostics (CODX), iBio (IBIO), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP) and Aurora Cannabis (ACB).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Cannabis
• Current Symbol: OTCMKTS:OWCP
• CIK: 1431934
• Web: www.owcpharma.com
• Phone: 972722608004
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A